Copy Link Print Information

Ivuxolimab

Customer Review

Based on 1 Customer Validation

Ivuxolimab is a fully human IgG2 agonist targeting OX40 (CD134), which selectively binds to the OX40 receptor on the surface of activated CD4+ and CD8+ T cells without inducing antibody-dependent cytotoxicity. Ivuxolimab can promote T cell proliferation, survival and cytokine (such as IFN-γ, IL-2) secretion, inhibit regulatory T cell function, and enhance anti-tumor immune response. Ivuxolimab can be used in the study of melanoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, etc.

For research use only. We do not sell to patients.

  • Purity: ≥99.0%
  • CAS No.: 2128729-41-7
  • Molecular Weight:142.72 kDa
  • Storage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Ivuxolimab
  • Experimental Validation Results for Ivuxolimab
  • Experimental Validation Results for Ivuxolimab
  • Ivuxolimab Chemical Structure
    Ivuxolimab Chemical Structure
CAS No.: 2128729-41-7
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

All Interleukin Related Isoforms

More
Keywords
100 mg

Get Quote In-stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    Human IgG2 kappa

  • 1/16

    Immobilized OX40/TNFRSF4 Protein, Human (HEK293, His, HY-P7394) can bind Ivuxolimab. The EC50 for this effect is 20.45 ng/mL.

  • 1/16

    Flow cytometric analysis of 1X106 500 ng/mL anti-CD3 and 500 ng/mL ant-CD28 co-stimulated Jurkat cells(24h) with Ivuxolimab (HY-P99159, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG2 kappa (HY-P99002, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

  • Ivuxolimab Chemical Structure
    1/16
  • Ivuxolimab
  • Immobilized OX40/TNFRSF4 Protein, Human (HEK293, His, HY-P7394) can bind Ivuxolimab. The EC50 for this effect is 20.45 ng/mL.
  • Flow cytometric analysis of 1X106 500 ng/mL anti-CD3 and 500 ng/mL ant-CD28 co-stimulated Jurkat cells(24h) with Ivuxolimab (HY-P99159, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG2 kappa (HY-P99002, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).